<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - VENLAFAXINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>VENLAFAXINE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#treatmentCessation" data-toggle="tab">Treatment cessation</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Major depression</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 75 mg daily in 2 divided doses, then increased if necessary up to 375 mg daily, dose to be increased if necessary at intervals of at least 2 weeks, faster dose titration may be necessary in some patients; maximum 375 mg per day.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 75 mg once daily, increased if necessary up to 375 mg once daily, dose to be increased if necessary at intervals of at least 2 weeks, faster dose titration may be necessary in some patients; maximum 375 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Generalised anxiety disorder</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                75 mg once daily, increased if necessary up to 225 mg once daily, dose to be increased at intervals of at least 2 weeks; maximum 225 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Social anxiety disorder</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                75 mg once daily, there is no evidence of greater efficacy at higher doses, increased if necessary up to 225 mg once daily, dose to be increased if necessary at intervals of at least 2 weeks; maximum 225 mg per day.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>A serotonin and noradrenaline re-uptake inhibitor.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid unless potential benefit outweighs risk&#8212;toxicity in <i>animal</i> studies.</p><p>Risk of withdrawal effects in neonate.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Consider reducing dose by 50% in mild or moderate impairment; use with caution and reduce dose by at least 50% in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Use half normal dose (immediate-release tablets may be given once daily) if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
        
            <section class="generalInformation">
              <p>Use with caution.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Conditions associated with high risk of cardiac arrhythmia</li>
            <li>uncontrolled hypertension</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abnormal dreams, anorexia, anxiety, anxiety (on withdrawal), asthenia, changes in serum cholesterol, chills, confusion, constipation, difficulty with micturition, dizziness, dizziness (on withdrawal), drowsiness, dry mouth, gastro-intestinal disturbances (on withdrawal), headache, headache (on withdrawal), hypertension, hypertonia, insomnia, menstrual disturbances, mydriasis, nausea, nervousness, palpitation, paraesthesia (on withdrawal), sensory disturbances, sexual dysfunction, sleep disturbances (on withdrawal), sweating, sweating (on withdrawal), tremor, tremor (on withdrawal), vasodilatation, visual disturbances, vomiting, weight changes, yawning,
              </p>
              <p>
                <strong>uncommon:</strong> Agitation, alopecia, angioedema, apathy, arrhythmias, bleeding disorders, bruxism, diarrhoea, ecchymosis, gastro-intestinal haemorrhage, hallucinations, incoordination, myoclonus, photosensitivity, postural hypotension, rash, taste disturbance, tinnitus, urinary retention,
              </p>
              <p>
                <strong>rare:</strong> Akathisia, extrapyramidal symptoms, hypomania, mania, seizures, urinary incontinence,
              </p>
              <p>
                <strong>veryRare:</strong> Angle-closure glaucoma,
              </p>
              <p>
                <strong>notKnown:</strong> Aggression, blood dyscrasias, delirium, hepatitis, hyperprolactinaemia, hypotension, neuroleptic malignant syndrome, pancreatitis, pruritus, QT interval prolongation, rhabdomyolysis, Stevens-Johnson syndrome, suicidal behaviour, syndrome of inappropriate anti-diuretic hormone secretion, urticaria, vertigo,
              </p>
        
        
            <section class="advice">
                <h3>Hyponatraemia and antidepressant therapy</h3>
              <p>Hyponatraemia (usually in the elderly and possibly due to inappropriate secretion of antidiuretic hormone) has been associated with all types of antidepressants; however, it has been reported more frequently with SSRIs than with other antidepressants. Hyponatraemia should be considered in all patients who develop drowsiness, confusion, or convulsions while taking an antidepressant.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>Depressive illness in children and adolescents</h3>
              <p>The balance of risks and benefits for the treatment of depressive illness in individuals under 18 years is considered unfavourable. Clinical trials have failed to show efficacy and have shown an increase in harmful outcomes. However, it is recognised that specialists may sometimes decide to use venlafaxine in response to individual clinical need; children and adolescents should be monitored carefully for suicidal behaviour, self-harm or hostility, particularly at the beginning of treatment.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Diabetes
          </li>
          <li>
            heart disease (monitor blood pressure)
          </li>
          <li>
            history of bleeding disorders
          </li>
          <li>
            history of epilepsy
          </li>
          <li>
            history or family history of mania
          </li>
          <li>
            susceptibility to angle-closure glaucoma
          </li>
        </ul>
      </section>





      <section class="tab-pane" id="treatmentCessation">
        <h2>Advice regarding ceasing treatment</h2>

            <section class="treatmentCessation">
              <p>Associated with a higher risk of withdrawal effects compared with other antidepressants.</p>
            </section>
            <section class="treatmentCessation">
              <p>Gastro-intestinal disturbances, headache, anxiety, dizziness, paraesthesia, tremor, sleep disturbances, and sweating are most common features of withdrawal if treatment stopped abruptly or if dose reduced markedly; dose should be reduced over several weeks.</p>
            </section>
      </section>








      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of VENLAFAXINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,
            powder,

            <div id="PHP77780"><a href="../medicinalForm/PHP77780.html" data-target="#PHP77780" data-action="load">Tablet</a></div>
            <div id="PHP77809"><a href="../medicinalForm/PHP77809.html" data-target="#PHP77809" data-action="load">Modified-release tablet</a></div>
            <div id="PHP77816"><a href="../medicinalForm/PHP77816.html" data-target="#PHP77816" data-action="load">Modified-release capsule</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
